Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Slides:

Advertisements

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Advertisements

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Su K. Metcalfe, MD, MPH, Michael T

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients Camilla Maria T. Sagerup, MD, Milada.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer Boris Sepesi, MD, Kathryn A. Gold, MD,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Frank Detterbeck, MD Journal of Thoracic Oncology

Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma Nader Abedallaa, MD, Lise Tremblay, MD, Charlotte.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Ann G. Schwartz, PhD, Michele L. Cote, PhD, Angela S

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Clinical Relevance of Our Multimodality Prognostic Score

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Validation of the Proposed International Association for the Study of Lung Cancer Non- small Cell Lung Cancer Staging System Revisions for Advanced Bronchioloalveolar.

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Ethnic Differences in the Management of Lung Cancer in New Zealand

Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J

International Thymic Malignancies Interest Group: A Way Forward

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Barbara J.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Presentation transcript:

Ethnic Disparities in Conditional Survival of Patients with Non-small Cell Lung Cancer Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD Journal of Thoracic Oncology Volume 2, Issue 3, Pages 180-190 (March 2007) DOI: 10.1097/JTO.0b013e318031cd4e Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Change in hazard rate in a typical actuarial life table survival curve leading to change in conditional survival. The instantaneous hazard rate can be represented by the slope of the survival curve. At point A (Year 1), the slope is greater than at point B (Year 6), indicating a higher hazard rate at Year 1 compared with Year 6. This change in slope leads to a relative increase in conditional survival. The 5-year conditional survival after 1 year is the survival at point B divided by the survival at point A: S6/S1 = 0.115/0.399 = 0.288. Journal of Thoracic Oncology 2007 2, 180-190DOI: (10.1097/JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Ten-year overall survival for all patients with non-small cell lung cancer, grouped by ethnicity. Journal of Thoracic Oncology 2007 2, 180-190DOI: (10.1097/JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Five-year conditional survival for all patients with non-small cell lung cancer, grouped by ethnicity. Journal of Thoracic Oncology 2007 2, 180-190DOI: (10.1097/JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Five-year conditional survival for patients with non-small cell lung cancer, by stage and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, 180-190DOI: (10.1097/JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Five-year conditional survival for patients with non-small cell lung cancer, by stage and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, 180-190DOI: (10.1097/JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Five-year conditional survival for patients with non-small cell lung cancer, by sex and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, 180-190DOI: (10.1097/JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Five-year conditional survival for patients with non-small cell lung cancer, by age and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, 180-190DOI: (10.1097/JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Five-year conditional survival for patients with non-small cell lung cancer, by histology and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, 180-190DOI: (10.1097/JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Five-year conditional survival for patients with non-small cell lung cancer, by histology and ethnicity. *Results suppressed for small groups in which the standard error was >10%. Journal of Thoracic Oncology 2007 2, 180-190DOI: (10.1097/JTO.0b013e318031cd4e) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions